These observations together with the association of increased SIPL1 GCN and upregulation of the SIPL1 mRNA with reduction in the survival of patients with ER+ and PR+ breast cancer in the Oncomine datasets demonstrate a positive association between SIPL1 expression and ER+ and PR+ cancers. Here, SHARPIN is linked to breast carcinoma.